Nexplanon (Etonogestrel)

Etonogestrel suppresses the mid‑cycle luteinizing hormone surge, thereby inhibiting ovulation. It also thickens cervical mucus, making sperm penetration difficult, and induces endometrial changes that are less suitable for implantation. These combined actions provide effective contraception.

The implant contains a fixed 68 mg dose of etonogestrel released continuously. The prescribing clinician determines placement and duration; no daily dosing is required by the patient. The device is typically effective for up to three years before replacement.

Nexplanon is not indicated for use during pregnancy; it is intended to prevent pregnancy. If pregnancy occurs, the implant should be removed. Limited data exist for breastfeeding, and clinicians weigh benefits against potential risks before continuation.

Enquiries are submitted via the product page on gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with oral combined pills, Nexplanon offers a single‑procedure, three‑year protection without daily adherence. Unlike intrauterine devices, it does not require uterine insertion and may have a different side‑effect profile, such as more frequent changes in menstrual bleeding patterns.

The implant should be stored at ambient temperature, below 25 °C, in its original sealed packaging. It must be protected from moisture and direct sunlight. Healthcare providers should handle it with aseptic technique during insertion and removal.

A trained healthcare professional inserts the 68 mg etonogestrel implant subcutaneously in the inner side of the upper arm using a sterile applicator. The procedure is performed in an outpatient setting, and the implant remains in place for up to three years before replacement.

Although rare, serious adverse events can include deep vein thrombosis, pulmonary embolism, severe allergic reactions, infection at the insertion site, and ectopic pregnancy if contraception fails. Patients should seek immediate medical attention if they experience symptoms such as unexplained leg swelling, chest pain, or severe skin reactions.

Women with a history of thromboembolic disorders, active liver disease, hormone‑sensitive cancers, unexplained vaginal bleeding, or known hypersensitivity to etonogestrel or any component of the implant should avoid its use. Contraindications are confirmed by the prescribing clinician.